Dianabol and Erythropoietin (EPO) Interaction: Monitor | Peptide Database

FDA-approved for the treatment of major depressive disorder, though it is rarely used as a primary antidepressant today due to the availability of SSRIs and SNRIs with more favorable side effect profiles for daytime use. Antidepressant doses range from 150-400 mg/day, significantly higher than the doses used for sleep. The most common clinical use of trazodone today. Low doses (25-100 mg) at bedtime reduce sleep onset latency, improve sleep continuity, and enhance slow-wave sleep. Multiple studies support its efficacy, and it is the most frequently prescribed off-label medication for insomnia in the United States. Particularly valued because it avoids the dependence and rebound insomnia associated with benzodiazepines and Z-drugs. Extremely popular in the bodybuilding and PED community for managing sleep disruption caused by anabolic steroids, particularly trenbolone (19-nortestosterone derivatives). Trenbolone is notorious for causing severe insomnia and night sweats, and trazodone at 50-100 mg is one of the most reliable and accessible solutions. Its non-addictive profile makes it suitable for use throughout entire steroid cycles. Useful for patients whose insomnia is driven by anxiety or racing thoughts at bedtime. The 5-HT2A antagonism and mild anxiolytic properties help quiet mental activity without the cognitive impairment of benzodiazepines. Often added to an existing SSRI or SNRI regimen specifically to address insomnia. Low-dose trazodone at bedtime can complement a daytime antidepressant without significant drug interaction concerns at typical doses.

FDA-approved (as Renova 0.05%) for the mitigation of fine facial wrinkles caused by chronic sun exposure. Clinical trials demonstrate measurable improvement in fine lines, tactile roughness, and mottled hyperpigmentation with 24-48 weeks of use. Accelerates turnover of melanin-laden keratinocytes, reducing the appearance of sunspots, melasma, and post-inflammatory hyperpigmentation. Often combined with hydroquinone and a corticosteroid in the classic Kligman formula. Improves tactile smoothness and skin surface regularity by normalizing the keratinization process and promoting orderly epidermal differentiation. Stimulates new collagen deposition in the papillary dermis, partially reversing the collagen degradation caused by UV-induced photoaging. Measurable increases in procollagen I have been documented histologically. First-line topical retinoid for non-inflammatory acne. Normalizes follicular keratinization, preventing the formation of microcomedones that are the precursor to all acne lesions. Effective as monotherapy for mild inflammatory acne and as combination therapy with benzoyl peroxide or topical antibiotics for moderate acne. Reduces both comedonal and papulopustular lesions. Recommended as long-term maintenance to prevent acne relapse after initial clearance. Low-concentration formulations (0.025%) are well-tolerated for indefinite maintenance use.